AGTC to Present Preclinical Research Supporting Gene Therapy Platform in Frontotemporal Dementia at the 25th Annual Meeting of the American Society of Gene & Cell Therapy
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced preclinical data presented at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) that expands the potential utility of its gene therapy platform to address neurogenerative diseases, such as frontotemporal dementia, and to demonstrate robust gene expression using hybrid dual AAV vectors. The research will be featured in poster presentations at the in-person meeting taking place May 16-19, 2022 in Washington, D.C.
“We are excited by the progress we’ve seen to date with our gene therapies in ophthalmic diseases and are continuing to assess the potential of our differentiated platform to treat a range of rare and debilitating diseases – including neurodegenerative diseases like dementia,” said Dr. Susan Schneider, Chief Medical Officer of AGTC. “We believe the preclinical findings in frontotemporal dementia are particularly encouraging and look forward to continuing our research to support a potential future Investigational New Drug Application filing.”
AGTC presentations at ASGCT 2022:
AVrh10-Based Gene Therapy for the Treatment of Frontotemporal Dementia Caused by GRN Mutations (Abstract #198)
Gene Therapy for Stargardt Disease Using Hybrid Dual AAV Vectors to Express ABCA4 (Abstract #306)
Poster # M-187
Location: Hall D